drugset / Trial / NCT01348139

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

NCT01348139

Phase 2 Completed 39 enrolled AstraZeneca
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of single doses of three different dry powder inhalation formulations of AZD3199 administered via Single Inhalation Device (SID) compared to AZD3199 administered via Turbuhaler™ Inhaler and compared to placebo in patients with persistent asthma.

Timeline

Start
2011-05
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD3199 Unknown 300 ug Inhaled
Subject AZD3199 Unknown 800 ug Inhaled
Subject AZD3199 Unknown 880 ug Inhaled
Subject AZD3199 Unknown 1200 ug Inhaled
Subject AZD3199 Unknown 1400 ug Inhaled

Indications